Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial involved adults with psoriasis and was conducted in two parts. In Part 1, 175 participants were assigned to receive ABP 501 (a medicine being compared to an existing treatment) and 175 were assigned to receive adalimumab (the existing, approved treatment), running for 16 weeks. In Part 2, participants continued into a longer follow-up phase through to around week 50, where some stayed on the same medicine they started with, and one group switched from adalimumab to ABP 501. The trial was measuring changes in psoriasis severity using a scoring system called the PASI (Psoriasis Area and Severity Index), which rates the redness, thickness, and scaliness of skin patches on a scale from 0 to 72 — with higher numbers meaning more severe psoriasis. The reported data shows that by week 16, participants in the ABP 501 group had, on average, an approximately 81% improvement in their PASI score from where they started, while the adalimumab group had an approximately 83% improvement. When looking at the proportion of people whose PASI score improved by 75% or more — a commonly used marker in psoriasis research — the reported data shows around 74% of the ABP 501 group and around 83% of the adalimumab group reached that level by week 16. By week 32, the reported figures for that same marker were approximately 83%, 85%, and 85% across the three continuing groups respectively, and by week 50 they were approximately 85%, 87%, and 81%. The reported data shows that these figures remained broadly similar across all three groups through weeks 32 and 50, including the group that switched from adalimumab to ABP 501 partway through. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 28755394) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Psoriasis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are a man or woman aged 18 to 75 years old
- You have had moderate to severe plaque psoriasis that has been stable for at least 6 months before the start of the trial
- Your psoriasis covers at least 10% of your body surface area and meets certain severity scores measured by a doctor at screening
- You have no known history of active tuberculosis
- Your doctor has determined that you are a suitable candidate for systemic (whole-body) treatment or light therapy for your psoriasis
- You have previously tried at least one standard psoriasis treatment that either did not work well enough, you could not tolerate, or you were unable to use for medical reasons
Who may not be able to join:
- You currently have other forms of psoriasis or other skin conditions, such as eczema, at the time of screening
- You are currently using certain treatments that are not allowed in this trial
- You have previously used 2 or more biologic medicines to treat your psoriasis
- You have previously received adalimumab (also known as Humira) or a similar biologic medicine (biosimilar) to it
Important: Other eligibility requirements not listed here may also apply. Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: MD, Amgen
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
1 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Percent Improvement From Baseline in Psoriasis Area and Severity Index (PASI) at Week 16
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.